{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:42:48Z","timestamp":1785368568656,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Danish Comprehensive Cancer Center Brain Tumor Center","award":["R295-A16770"],"award-info":[{"award-number":["R295-A16770"]}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Brain Tumor Association and NOCRiiC"},{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Management of recurrent glioblastoma (rGBM) remains challenging, particularly for deep-seated or eloquent recurrences not amenable to open surgery, and no standardized effective treatment exists for recurrent disease. European data on MR-guided laser interstitial thermal therapy (LITT) are scarce. This study presents the first Scandinavian experience with LITT for IDH-wild-type rGBM, within publicly funded healthcare systems providing population-wide access to care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective data from 30 consecutive patients with histologically confirmed IDH-wild-type rGBM treated with LITT at two Scandinavian centers between January 2019 and May 2024 were analyzed. Demographics, ECOG performance status, procedural parameters, adverse events, and survival outcomes were collected. Kaplan\u2013Meier estimates were used for progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 57\u00a0years (SD 10.2); 83% had pre-LITT ECOG 0. Complete and\u2009\u2265\u200990% ablation of contrast enhancement was achieved in 83% and 97% of cases, respectively. Median hospital stay was 1\u00a0day, with 87% discharged by day 2. Adverse events occurred in 33%, predominantly transient neurological deficits (27%) and infections (7%); 10% had persistent deficits. Median OS after LITT was 13.5\u00a0months (95% CI 11.6\u201320.5) and median PFS was 4.3\u00a0months (95% CI 2.6\u20139.1); 37% remained progression-free at 6\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LITT was feasible and well tolerated in this two-center Scandinavian cohort, with short hospitalization and low morbidity. Survival outcomes were within the range reported in previous international series. While these findings provide preliminary real-world data on LITT use within Scandinavian publicly funded healthcare systems, the limited sample size and retrospective design preclude definitive conclusions. Prospective, controlled studies are warranted to clarify the clinical role of LITT in recurrent glioblastoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00701-026-06771-0","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:26:01Z","timestamp":1769145961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study"],"prefix":"10.1007","volume":"168","author":[{"given":"Silas H.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Skj\u00f8th-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margret","family":"Jensdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Urup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Bartek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"6771_CR1","doi-asserted-by":"publisher","unstructured":"Aa A, K G, Ij C, Sr M, A M, S M, B H, Hs P, T U (2021) A prognostic model for glioblastoma patients treated with standard therapy based on a prospective cohort of consecutive non-selected patients from a single institution. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.597587","DOI":"10.3389\/fonc.2021.597587"},{"issue":"13","key":"6771_CR2","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","volume":"14","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, Fersht N, Mulholland P (2022) Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel) 14(13):3161","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6771_CR3","doi-asserted-by":"publisher","first-page":"vdab164","DOI":"10.1093\/noajnl\/vdab164","volume":"3","author":"OH Butt","year":"2021","unstructured":"Butt OH, Zhou AY, Huang J et al (2021) A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neuro-Oncol Adv 3(1):vdab164","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"6771_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1227\/neu.0000000000002093","volume":"91","author":"HA Fadel","year":"2022","unstructured":"Fadel HA, Haider S, Pawloski JA, Zakaria HM, Macki M, Bartlett S, Schultz L, Robin AM, Kalkanis SN, Lee IY (2022) Laser interstitial thermal therapy for first-line treatment of surgically accessible recurrent glioblastoma: outcomes compared with a surgical cohort. Neurosurgery 91(5):701\u2013709","journal-title":"Neurosurgery"},{"issue":"01","key":"6771_CR5","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2021-0013","volume":"11","author":"H Hwang","year":"2022","unstructured":"Hwang H, Huang J, Khaddour K, Butt OH, Ansstas G, Chen J, Katumba RG, Kim AH, Leuthardt EC, Campian JL (2022) Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab. CNS Oncol 11(01):CNS81","journal-title":"CNS Oncol"},{"issue":"2","key":"6771_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nec.2022.12.003","volume":"34","author":"M Jensdottir","year":"2023","unstructured":"Jensdottir M, Sandvik U, Jakola AS et al (2023) Learning curve analysis and adverse events after implementation of neurosurgical laser ablation treatment: a population-based single-institution consecutive series. Neurosurg Clin N Am 34(2):259\u2013267","journal-title":"Neurosurg Clin N Am"},{"key":"6771_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.822362","author":"S Katzendobler","year":"2022","unstructured":"Katzendobler S, Do A, Weller J et al (2022) Diagnostic yield and complication rate of stereotactic biopsies in precision medicine of gliomas. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.822362","journal-title":"Front Neurol"},{"key":"6771_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114311","volume":"185","author":"EC Lerner","year":"2022","unstructured":"Lerner EC, Edwards RM, Wilkinson DS, Fecci PE (2022) Laser ablation: heating up the anti-tumor response in the intracranial compartment. Adv Drug Deliv Rev 185:114311","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"6771_CR9","doi-asserted-by":"publisher","first-page":"e0148613","DOI":"10.1371\/journal.pone.0148613","volume":"11","author":"EC Leuthardt","year":"2016","unstructured":"Leuthardt EC, Duan C, Kim MJ, Campian JL, Kim AH, Miller-Thomas MM, Shimony JS, Tran DD (2016) Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier. PLoS ONE 11(2):e0148613","journal-title":"PLoS ONE"},{"key":"6771_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.wneu.2017.05.009","volume":"104","author":"S-A Morris","year":"2017","unstructured":"Morris S-A, Rollo M, Rollo P, Johnson J, Grant GA, Friedman E, Kalamangalam G, Tandon N (2017) Prolonged blood-brain barrier disruption following laser interstitial ablation in epilepsy: a case series with a case report of postablation optic neuritis. World Neurosurg 104:467\u2013475","journal-title":"World Neurosurg"},{"key":"6771_CR11","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_538_2020","volume":"12","author":"IS Neville","year":"2021","unstructured":"Neville IS, Dos Santos AG, Almeida CC, Abaurre LB, Wayhs SY, Feher O, Teixeira MJ, Lepski G (2021) Reoperation for recurrent glioblastomas: What to expect? Surg Neurol Int 12:42","journal-title":"Surg Neurol Int"},{"issue":"1","key":"6771_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00701-024-06238-0","volume":"166","author":"SH Nielsen","year":"2024","unstructured":"Nielsen SH, Rasmussen R (2024) MR-guided laser interstitial thermal therapy in the treatment of brain tumors and epilepsy. Acta Neurochir 166(1):344","journal-title":"Acta Neurochir"},{"key":"6771_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf148","author":"SH Nielsen","year":"2025","unstructured":"Nielsen SH, Skj\u00f8th-Rasmussen J, Larsen VA, Carlsen JF, Larsson HBW, Christoffersen C, Rasmussen R, Hansen AE (2025) Blood-brain barrier disruption following MR-guided laser interstitial thermal therapy. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaf148","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"6771_CR14","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/ijms25052529","volume":"25","author":"E Obrador","year":"2024","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M et al (2024) Glioblastoma therapy: past, present and future. Int J Mol Sci 25(5):2529","journal-title":"Int J Mol Sci"},{"key":"6771_CR15","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.wnsx.2022.100136","volume":"17","author":"PJ O\u2019Halloran","year":"2023","unstructured":"O\u2019Halloran PJ, Henry J, Amoo M, Kalyvas A, Mohan N, Zadeh G, Kalia SK, Kongkham PN (2023) LITTing up Gliomas\u2014is the future bright? World Neurosurgery: X 17:100136","journal-title":"World Neurosurgery: X"},{"issue":"1","key":"6771_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00701-024-06335-0","volume":"166","author":"R Rasmussen","year":"2024","unstructured":"Rasmussen R, Nielsen SH (2024) How i do it: MRI-guided stereotactic navigation for laser interstitial thermal therapy. Acta Neurochir (Wien) 166(1):444","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"6771_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61925-3","volume":"14","author":"AM Rykkje","year":"2024","unstructured":"Rykkje AM, Carlsen JF, Larsen VA, Skj\u00f8th-Rasmussen J, Christensen IJ, Nielsen MB, Poulsen HS, Urup TH, Hansen AE (2024) Prognostic relevance of radiological findings on early postoperative MRI for 187 consecutive glioblastoma patients receiving standard therapy. Sci Rep 14(1):10985","journal-title":"Sci Rep"},{"issue":"2","key":"6771_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/lsm.10181","volume":"33","author":"M Sabel","year":"2003","unstructured":"Sabel M, Rommel F, Kondakci M, Gorol M, Willers R, Bilzer T (2003) Locoregional opening of the rodent blood\u2013brain barrier for paclitaxel using Nd:YAG laser-induced thermo therapy: a new concept of adjuvant glioma therapy? Lasers Surg Med 33(2):75\u201380","journal-title":"Lasers Surg Med"},{"issue":"1","key":"6771_CR19","first-page":"1","volume":"16","author":"O Sacko","year":"2021","unstructured":"Sacko O, Benouaich-Amiel A, Brandicourt P et al (2021) The impact of surgery on the survival of patients with recurrent glioblastoma. Asian J Neurosurg 16(1):1\u20137","journal-title":"Asian J Neurosurg"},{"issue":"1","key":"6771_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa071","volume":"2","author":"A Salehi","year":"2020","unstructured":"Salehi A, Paturu MR, Patel B et al (2020) Therapeutic enhancement of blood\u2013brain and blood\u2013tumor barriers permeability by laser interstitial thermal therapy. Neuro-Oncol Adv 2(1):vdaa071","journal-title":"Neuro-Oncol Adv"},{"key":"6771_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.wneu.2024.10.022","volume":"193","author":"MP Seaton","year":"2025","unstructured":"Seaton MP, Schmidt JC, Brown NJ, Sahyouni R, Khalessi AA, Ben-Haim S, Gonda DD (2025) Contemporary applications of laser interstitial thermal therapy: a comprehensive systematic review. World Neurosurg 193:356\u2013372","journal-title":"World Neurosurg"},{"issue":"2","key":"6771_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuchi.2025.101629","volume":"71","author":"E Sharma","year":"2025","unstructured":"Sharma E, Sahin OK, \u0141ajczak P, Rajab N, Ahmed AR, Silva YP, Bakhsh A, Chatterjee A, Raake M, Fagundes W (2025) Synergistic effects of laser interstitial thermal therapy (LITT) and immunotherapy for brain tumor recurrence: a systematic review and meta-analysis. Neurochirurgie 71(2):101629","journal-title":"Neurochirurgie"},{"issue":"1","key":"6771_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11060-020-03557-x","volume":"151","author":"DH Shin","year":"2021","unstructured":"Shin DH, Melnick KF, Tran DD, Ghiaseddin AP (2021) In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas. J Neurooncol 151(1):85\u201392","journal-title":"J Neurooncol"},{"issue":"2","key":"6771_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02656736.2020.1746413","volume":"37","author":"ES Srinivasan","year":"2020","unstructured":"Srinivasan ES, Sankey EW, Grabowski MM, Chongsathidkiet P, Fecci PE (2020) The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. Int J Hyperthermia 37(2):27\u201334","journal-title":"Int J Hyperthermia"},{"issue":"10","key":"6771_CR25","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"key":"6771_CR26","doi-asserted-by":"crossref","unstructured":"Yu JS, Meade SM, Zhao R et al (2025) Expedited chemoradiation after laser interstitial thermal therapy (LITT) is feasible and safe in patients with newly diagnosed glioblastoma. Neuro-Oncol Adv vdaf038","DOI":"10.1093\/noajnl\/vdaf038"},{"issue":"1","key":"6771_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-024-02409-w","volume":"47","author":"X Zhao","year":"2024","unstructured":"Zhao X, Li R, Guo Y, Wan H, Zhou D (2024) Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis. Neurosurg Rev 47(1):159","journal-title":"Neurosurg Rev"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-026-06771-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-026-06771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-026-06771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:33:49Z","timestamp":1769153629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-026-06771-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6771"],"URL":"https:\/\/doi.org\/10.1007\/s00701-026-06771-0","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Danish Research Ethics Committee (Project ID: H-21047703) and the Swedish Ethical Review Authority (DNR 2017\/1760\u201331 and 2025\u201303035-02), and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Danish cohort was prospectively collected as part of routine clinical data acquisition and approved by the National Danish Research Ethics Committee. The Swedish cohort was based on retrospectively collected clinical data approved by the Swedish Ethical Review Authority. In both cohorts, all data were de-identified prior to analysis, and the requirement for individual patient consent to participate was waived in accordance with national regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Silas Haahr Nielsen and Rune Rasmussen have received travel grants from Medtronic for attending conferences. Additionally, Medtronic has co-sponsored a conference for which they served as hosts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}